Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Jayson Rieger will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026 at 10:30am ET.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Jayson Rieger will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026 at 10:30am ET.
According to the company, a live webcast will be available on Verrica's investor website and a replay will be posted and available for 90 days.
Reported Q3 2025 revenue, YCANTH growth and regulatory feedback alongside small net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
shelf registration statement, pre-funded warrants, series c warrant, series b warrants, +4 more
8 terms
shelf registration statementregulatory
"is registering up to 14,756,230 shares of common stock for resale by existing stockholders under a shelf registration statement."
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
pre-funded warrantsfinancial
"up to 5,305,164 shares issuable upon exercise of pre-funded warrants, and up to 2,951,240 shares issuable upon exercise of common warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
series c warrantfinancial
"Each unit also included a Series C warrant, giving the right to buy one fourth of a share"
A Series C warrant is a contract issued alongside a Series C financing round that gives the holder the right to buy company shares at a set price for a limited time. Think of it like a discounted ticket to buy stock later: it can offer extra upside if the company’s value rises, but it also represents potential future dilution for existing shareholders and can change the ownership mix and value per share.
series b warrantsfinancial
"The filing lists Series B Warrants, immediately exercisable, for 224,719 shares of Verrica common stock"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
reverse stock splitfinancial
"did not reflect Verrica’s 1-for-10 reverse stock split that took effect on July 24, 2025."
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
pipe financingfinancial
"announced a private placement PIPE financing raising approximately $50 million in gross proceeds"
Pipe financing is a way for companies to raise money quickly by selling new shares or bonds directly to investors, often before their stock is publicly traded or in the early stages of a project. It’s similar to a company securing a loan from investors, providing quick capital needed for growth or operations. For investors, it can offer opportunities for early involvement and potentially higher returns, but it may also carry increased risk due to the immediate nature of the deal.
phase 3medical
"global Phase 3 program evaluating YCANTH (VP-102) for common warts."
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
molluscum contagiosummedical
"YCANTH for the treatment of molluscum contagiosum."
Molluscum contagiosum is a common viral skin infection that causes small, painless bumps or lesions on the skin. While it primarily affects children and healthy adults, it can spread easily through skin contact. For investors, understanding health conditions like this highlights the importance of healthcare companies involved in treatments and the potential impact of infectious diseases on public health and economic stability.
WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston.
TD Cowen 46th Annual Health Care Conference, March 2-4, 2026 Event details: Date: Monday, March 2, 2026 Time: 10:30am ET Location: Boston, Massachusetts
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About Verrica Pharmaceuticals Inc. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Verrica (VRCA) present at the TD Cowen 46th Annual Health Care Conference?
Verrica will present on Monday, March 2, 2026 at 10:30am ET. According to the company, CEO Jayson Rieger will deliver the presentation in Boston during the conference running March 2-4, 2026.
How can investors watch Verrica's (VRCA) TD Cowen conference presentation on March 2, 2026?
Investors can access a live webcast via Verrica's investor site or the conference link. According to the company, the webcast is available on www.verrica.com under Investors/Presentations & Events.
Will Verrica (VRCA) provide a replay of the March 2, 2026 conference presentation?
Yes, a replay will be posted and available for 90 days after the presentation. According to the company, the replay will be accessible on the Verrica website shortly after the live webcast ends.
Who will present for Verrica (VRCA) at the TD Cowen healthcare conference on March 2, 2026?
Jayson Rieger, PhD, MBA, President and CEO, will present for Verrica. According to the company, he will represent Verrica and discuss company developments during the March 2, 2026 session.
Where is the TD Cowen 46th Annual Health Care Conference presentation by Verrica (VRCA) taking place?
The presentation will take place in Boston, Massachusetts as part of the TD Cowen conference. According to the company, Verrica's session is scheduled for March 2, 2026 at 10:30am ET.
How long will Verrica's (VRCA) conference replay remain available after the March 2, 2026 presentation?
The replay will remain available for 90 days following the presentation. According to the company, investors can view the replay on Verrica's investor website during that 90-day window.
